GlassScriptPhysician profile
Gina Danley Null
NPI 1851614648
$7,851.44
in general payments reported to CMS, 2019-2025
55 companies · $2,510 in 2025
The $2,510 reported for 2025 was more than what 95% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $363 · 2022: $1,344 · 2023: $1,679 · 2024: $1,956 · 2025: $2,510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,616 · Education: $529.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,616.11 |
| Education | $528.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $815.03 | 2023-2025 | |
| Daiichi Sankyo INC. | $548.45 | 2022-2025 | Enhertu, Datroway |
| Incyte Corporation | $527.82 | 2022-2025 | Zynyz, Monjuvi, Pemazyre |
| Astrazeneca Pharmaceuticals LP | $512.01 | 2022-2025 | Enhertu, Imfinzi, Tagrisso |
| Merck Sharp & Dohme LLC | $402.72 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Eisai INC. | $351.86 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $351.39 | 2022-2025 | Iclusig, Ninlaro, Fruzaqla |
| Exelixis INC. | $346.99 | 2022-2025 | Cabometyx |
| Seagen INC. | $340.39 | 2022-2023 | Tukysa |
| Lilly USA, LLC | $322.08 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Pfizer INC. | $296.51 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $261.00 | 2022-2025 | |
| Janssen Biotech, INC. | $244.28 | 2022-2025 | Darzalex, Tecvayli, Talvey |
| Glaxosmithkline, LLC. | $209.26 | 2022-2025 | Ojjaara, Jemperli, Zejula |
| Novartis Pharmaceuticals Corporation | $205.13 | 2022-2025 |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $193.03 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $156.01 | 2022-2025 | Opdivo, Opdualag, Augtyro |
| Regeneron Healthcare Solutions, INC. | $147.83 | 2022-2025 | Libtayo, Lynozyfic |
| Aveo Pharmaceuticals, INC. | $129.90 | 2022-2025 | Fotivda |
| Kite Pharma, INC. | $124.97 | 2023 | Yescarta |
| Astellas Pharma US INC | $120.02 | 2021-2025 | Vyloy |
| Pharmacyclics LLC, An Abbvie Company | $101.03 | 2023 | Imbruvica, Epkinly |
| Pharmaessentia USA Corporation | $83.35 | 2023-2025 | Besremi |
| Rigel Pharmaceuticals, INC. | $73.80 | 2023-2024 | Tavalisse, Rezlidhia |
| Sobi, INC | $64.33 | 2022-2024 | |
| Ipsen Biopharmaceuticals, INC | $60.10 | 2023-2024 | Onivyde, Somatuline Depot |
| G1 Therapeutics, INC. | $58.45 | 2022-2023 | Cosela |
| Gilead Sciences, INC. | $56.68 | 2022-2024 | |
| Coloplast Corp | $54.49 | 2021-2022 | |
| Antares Pharma, INC. | $52.27 | 2021 | |
| Celgene Corporation | $48.64 | 2022-2025 | Pomalyst, Opdivo |
| Beone Medicines USA, INC. | $47.06 | 2025 | Brukinsa |
| Pharmacosmos Therapeutics INC. | $44.38 | 2024 | Cosela, Monoferric |
| Endo Pharmaceuticals INC. | $40.65 | 2021 | |
| Dendreon Pharmaceuticals LLC | $39.87 | 2022 | |
| Tempus Ai, INC | $34.43 | 2024-2025 | Xt Cdx |
| Karyopharm Therapeutics INC. | $32.76 | 2025 | Xpovio |
| Puma Biotechnology, INC. | $32.19 | 2024 | |
| Urovant Sciences INC | $30.41 | 2022 | |
| Sumitomo Pharma America, INC. | $29.29 | 2024 | Orgovyx |
| Cti Biopharma Corp. | $29.05 | 2023 | Vonjo |
| Beigene USA, INC. | $23.05 | 2024 | Brukinsa |
| Janssen Pharmaceuticals, INC | $22.42 | 2023 | Xarelto |
| Genzyme Corporation | $19.87 | 2025 | |
| Blue Earth Diagnostics | $18.25 | 2021 | |
| Stemline Therapeutics INC. | $17.99 | 2024 | Orserdu |
| Sun Pharmaceutical Industries INC. | $17.24 | 2022 | |
| Iovance Biotherapeutics, INC. | $15.23 | 2025 | Amtagvi |
| Genentech USA, INC. | $15.11 | 2023 | Lunsumio, Polivy, Venclexta |
| Alexion Pharmaceuticals, INC. | $14.88 | 2025 | Ultomiris |
| Geron Corporation | $14.85 | 2025 | Rytelo |
| Tolmar Pharmaceuticals, INC. | $13.49 | 2021 | |
| Morphosys, US INC. | $13.27 | 2023 | Monjuvi |
| Axonics, INC. | $13.16 | 2022 | |
| Blueprint Medicines Corporation | $12.72 | 2023 | Ayvakit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gina Null listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.